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Abstract 
Extracellular acidosis resulting from intense metabolic activities in tumors promotes 
cancer cell migration, invasion and metastasis. While host cells die at low extracellular 
pH, cancer cells resist, as they are well equipped with transporters and enzymes to 
regulate intracellular pH homeostasis. A low extracellular pH further activates proteolytic 
enzymes that remodel the extracellular matrix to facilitate cell migration and invasion. 
Monocarboxylate transporter MCT1 is a passive transporter of lactic acid that has 
attracted interest as a target for small molecule drugs to prevent metastasis. In this 
study, we present evidence of a function for MCT1 in metastasis beyond its role as a 
transporter of lactic acid. MCT1 activated transcription factor NF-κB to promote cancer 
cell migration independently of MCT1 transporter activity. While pharmacological MCT1 
inhibition did not modulate MCT1-dependent cancer cell migration, silencing or genetic 
deletion of MCT1 in vivo inhibited migration, invasion and spontaneous metastasis. Our 
findings raise the possibility that pharmacological inhibitors of MCT1-mediated lactic acid 
transport may not effectively prevent metastatic dissemination of cancer cells.  
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Introduction 
Cancer cells deploy several strategies to survive and proliferate in poorly permissive 
tumor microenvironments characterized by hypoxia and nutrient deprivation. Among 
metabolic strategies, hypoxic/glycolytic cancer cells can cooperate with oxidative cancer 
cells by swapping glycolytic end-product lactic acid against blood-born glucose (1), and 
oxidative cancer cells can further obtain lactate by coopting stromal cell metabolism (2, 
3). At the core of these metabolic relationships, oxidative cancer cells use lactate as 
preferential oxidative fuel to glucose, thus sparing glucose for glycolytic cells (1).  
 Lactate exchanges in cancer are governed by monocarboxylate transporters 
(MCTs) of the SLC16 gene family that passively convey lactate and protons across the 
cell membrane (4). MCT1 and MCT4 are the main isoforms expressed by cancer cells 
(5). With a Km for lactate of 22-28 mM and a high turnover rate, hypoxia-inducible MCT4 
is adapted for lactic acid export by glycolytic cells (6, 7). Comparatively, MCT1 has a 
lower 3.5–10 mM Km for lactate (4). Considering that the average concentration of 
lactate is ~10 mM in human solid tumors (8) and that oxidative cancer cells consume 
lactate (1), MCT1 is optimized for lactic acid uptake by these cells. However, as a 
passive transporter, MCT1 can operate bidirectionally and has also been reported to 
facilitate lactic acid export from cancer cells (9-12). The directionality of MCT1-driven 
lactic acid transport indeed depends on the gradient of lactate and protons membranes.  
 In growing tumors, functional characterization recently revealed that MCTs are not 
only gatekeepers of intercellular metabolic cooperation, but also important regulators of 
angiogenesis. Lactate that enters into oxygenated endothelial cells and oxidative cancer 
cells via MCT1 indeed promotes angiogenesis as it acts as a hypoxia-mimetic that 
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activates transcription factors hypoxia-inducible factor-1 (HIF-1) and nuclear factor-κB 
(NF-κB), thereby stimulating the production of pro-angiogenic agents vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and interleukin-8 
(IL-8) (13). Consequently, pharmacological MCT1 inhibitors have been proposed to 
simultaneously inhibit lactate exchanges and angiogenesis in tumors with limited side 
effects (5, 14), making of them particularly good candidate drugs for anticancer 
treatment. Hence, MCT1 inhibitor AZD3965 is currently tested in Phase I/II clinical trials 
in patients with prostate cancer, gastric cancer or diffuse large B cell lymphoma 
(ClinicalTrials.gov, NCT01791595). 
 Advanced stage tumors often undergo a metastatic switch, and metastatic 
dissemination strongly limits curative opportunities. Identifying treatments capable of 
preventing metastasis is, therefore, an urgent task. At least 3 lines of evidence suggest 
that lactate and MCTs, especially MCT1, promote tumor metastasis. First, analyses of 
primary tumor biopsies from patients revealed that high levels of lactate predict the 
likelihood of tumor metastasis (15-18). Second, MCT1 forms stable heterocomplexes 
with chaperon protein CD147/basigin (19), and CD147 promotes cancer cell invasion 
and metastasis (20). Third, we and others recently reported that MCT1 stimulates the 
migration and invasion of (glucose-starved) cancer cells towards serum or glucose (12, 
21-23). Gray et al. (24) further proposed that MCT1 could facilitate cancer cell migration 
independently of its transporter activity based on the observation that silencing MCT1 
with a shRNA inhibited the in vitro scattering of prostate cancer cells stimulated with 
epithelial growth factor (EGF) or hepatocyte growth factor (HGF), whereas AZD3965 
used at concentrations up to 10 µM did not. In this context, we analyzed the contribution 
of MCT1 to the tumor metastasis. We report that MCT1 activates NF-κB to promote 
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cancer cell migration independently of its transport activity. Consequently, MCT1 
silencing or its genetic deletion inhibited cancer cell migration and invasion in vitro and 
spontaneous tumor metastasis in vivo.   
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Materials and Methods 
Cell culture and reagents 
Superinvasive SiHa-F3 and mitochondria-deficient SiHa ρ0 cells were generated from 
wild-type SiHa human cervix adenocarcinoma cells (obtained in 2010 from ATCC) as in 
reference (25). 4T1 mouse mammary carcinoma cells were a kind gift of Fred R. Miller 
(Karmanos Cancer Institute, Detroit, MI) in 2011. Cells were routinely cultured in DMEM 
containing 4.5 g/L (25 mM) glucose, GlutaMAX (Gibco), and 10% FBS (Sigma) in a 
humidified atmosphere at 37°C, 5% CO2. SiHa ρ0 further received 50 ng/mL of uridine 
(Sigma) and 1 mM of sodium pyruvate (Gibco). Cells were used from passage 2 to 
passage 15 after thawing and regularly tested for mycoplasma using the MycoAlert 
detection kit (Lonza). MCT1 inhibitors AR-C155858 (Tocris) and AZD3965 
(Selleckchem) were dissolved in DMSO. Tumor necrosis factor α (TNFα) was from 
Miltenyi, tetradecanoyl phorbol myristate acetate (TPA) from Sigma-Aldrich and NF-κB 
inhibitor BMS-345541 from Tocris. Unless stated otherwise, assays were performed in 
culture medium. 
 
Transfection and infection 
For luciferase expression, 4T1 were infected with lentiviruses carrying the luciferase 
sequence (Addgene 21471) following a previously disclosed protocol (25). 
 For MCT1 silencing with small interfering RNAs (siRNAs), SiHa cells were 
transfected with siCTR (Qiagen 1027281) or siMCT1 (Qiagen AAG AGG CUG ACU 
UUU CCA AAU) as previously described (26) and assayed 48 h after transfection. 
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 For MCT1 silencing with short hairpin RNAs (shRNAs), cells were infected with 
lentiviruses as previously described (27). shRNAs targeted human MCT1 (shMCT1; 
Thermo Scientific TRCN0000038339) or mouse MCT1 (shMCT1a; Thermo Scientific 
TRCN0000079545 and shMCT1b; Thermo Scientific TRCN0000079547). shCTR- and 
shMCT1-expressing SiHa-F3 cells were further infected with lentiviruses carrying green 
fluorescent protein (EGFP, Addgene 12252) or red fluorescent tdTomato (Addgene 
21374), and the cells were FACS-sorted on an Aria III cell sorter (BD Biosciences). In 
rescue experiments, mouse 4T1-shMCT1a cells were transfected with human wild-type 
MCT1 (hMCT1+) cDNA using pCMV6/Entry-mct1 plasmid (OriGene), and selected with 
G418 (400 µg/mL).  
For MCT1 deletion, SiHa-CRISPR-MCT1 cells were produced using Sigma 
LentiCRISPR (Target sequence: GTATAGTCATGATTGTTGGTGG) (27), and selected 
using puromycin. In rescue experiments, SiHa-CRISPR-MCT1 cells were transfected as 
in reference (28) with Cas9-resistant human MCT1 cDNA (3 conservative point 
mutations in target sequence: GTATAGTCATGATaGTgGGTGG) that was 
mutated/inactivated for proton- and lactate-binding sites (38K>R, 302D>R, 306R>D) 
(29) using pEX-K4-MCT1 plasmid (Eurofins). This mutant transgene was named 
hMCT1-. pEGFP-c1 (Clontech) was used as a negative and transfection-quality control. 
Cells were used 96 h after transfection. 
 
Western blotting 
Cells were lysed in RIPA buffer containing inhibitor cocktails of proteases (Sigma) and 
phosphatases (PhosSTOP; Roche), and western blotting was performed as previously 
described (30). Primary antibodies were: rabbit antibodies against MCT1 (Chemicon 
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#AB3538P), human MCT4 (Chemicon #AB3316P), mouse MCT4 (Santa-Cruz #sc-
50329), p65 (Cell Signaling #8242), p-Ser536-p65 (Cell Signaling #3033); and mouse 
antibodies against human CD147 (BD Biosciences #555961), HSP-90 (BD Biosciences 
#610419), and β-actin (Sigma #A5441). Secondary antibodies were HRP-coupled goat 
anti-rabbit and anti-mouse (Jackson).  
 
Cell viability and proliferation assay 
At Day 0, 2,000 SiHa or 4,000 4T1 cells per well were seeded in 96-well plates. Images 
were daily captured on a SpectraMax miniMax300 imaging cytometer (Molecular 
Devices) and analyzed with the Softmax Pro software (Molecular Devices). Results were 
normalized to cell number at Day 0. 
 
Cell migration and invasion 
Migration was first assayed using a scratch test following a previously disclosed protocol 
(31). Cells in culture medium containing 0.5 µg/mL of proliferation inhibitor mitomycin C 
were allowed to migrate for 48 h in a humidified atmosphere at 37°C, 5% CO2. To 
measure scratch closure, images were captured every 4 h on an Axio Observer.Z1 time 
lapse microscope (Zeiss). Data were analyzed using ImageJ (NIH). 
 For transwell assays, cell migration was tested on a multiwell chemotaxis 
chamber (Neuro Probe) or using transwell inserts (Corning #353097). Briefly, 50,000 
cells in serum-free culture medium were seeded in the upper chamber of each well, and 
FBS 0.15% was used as a chemoattractant in the lower chamber. Invasion was assayed 
using transwell inserts (regular Corning #353097 and Fluoroblok Corning #351152) 
coated with growth factor-reduced and phenol red-free Matrigel (Corning #356231) 
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diluted 1:10 in PBS. Briefly, 100,000 cells in serum-free culture medium were seeded in 
the upper chamber of each well, and FBS 5% was used as a chemoattractant in the 
lower chamber. Cells were allowed to migrate for 16 h or to invade for 24 h in a 
humidified atmosphere at 37°C, 5% CO2. Migrated/invaded cells were then fixed with 
methanol. Non-fluorescent cells were stained with a 0.023% crystal violet solution. 
Images were captured on an AxioVert microscope equipped with an AxioCam-MRc 
camera (Zeiss), and cells were counted using ImageJ. 
 
Clonogenicity 
Clonogenicity was tested on noble agar 0.33% (Sigma). Colonies were allowed to grow 
for 14 days before staining with a saturated MTT solution (Calbiochem) diluted in PBS. 
Pictures were taken under a Stemi 2000-C dissection microscope (Zeiss), and colonies 
were counted using ImageJ.  
 
Metabolic assays 
Glucose consumption and lactate release were determined with enzymatic assays on a 
CMA 600 Microdialysis analyzer (CMA Microdialysis) following manufacturer’s 
instructions. Experimental conditions were: 150,000 SiHa cells/well for 24 h in 0.5 mL of 
culture medium and 100,000 4T1 cells/well for 24 h in 1 mL of culture medium. Results 
were normalized to total protein content (Bradford). 
 Intracellular lactate concentration was determined on adherent cells in 96-well 
plates that were incubated for 30 min in 100 µL of culture medium, washed with PBS 
and lysed in situ. Samples were analyzed using a lactate bioluminescent detection 
assay kit (kind gift from Promega) according to manufacturer's instructions. 
Research. 
on September 20, 2017. © 2017 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 21, 2017; DOI: 10.1158/0008-5472.CAN-17-0764 
10 
 
Bioluminescence was measured with a GloMax 96 Microplate luminometer (Promega). 
Data were normalized to cell number. 
 Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were 
measured on 20,000 cells/well using a Seahorse XF96 analyzer (Agilent) with a 
combination of XF cell mito stress kit (Agilent) and 2-deoxy-D-glucose (2DG, Sigma). 
Basal mitochondrial OCR is the difference between initial OCR and OCR after inhibition 
of the electron transport chain (ETC) by rotenone (0.5 µM) and antimycin A (0.5 µM). 
Maximal mitochondrial OCR is the difference between OCR after injection of uncoupler 
FCCP (1 µM) and OCR after injection of rotenone and antimycin A. Glycolytic ECAR is 
the difference between initial ECAR and ECAR after injection of 2DG (100 mM). All 
assays were performed in unbuffered serum-free DMEM supplemented with 10 mM D-
glucose and 2 mM L-glutamine, pH 7.4. Results were normalized to cell number or total 
protein content (Bradford). 
 
Determination of intracellular and perimembranous pH 
Intracellular pH (pHi) was determined on 20,000 cells with 5,6-carboxy-SNARF-1-
acetomethylester (SNARF-AM, Molecular Probes) and pH at the outer side of the cell 
membrane with N-(fluorescein-5-thiocarbamoyl)-1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolamine (fluorescein-DHPE, Molecular Probes), as previously reported 
(32). Calibration for pHi was performed on carboxy-SNARF-1-loaded cells treated with 
potassium/proton ionophore nigericin (2.5 µM) and hyperpotassic solutions at pH values 
ranging from 6.6 to 8.0. Calibration for extracellular membrane pH was performed with 
fluorescein-DHPE in solutions at pH 4.9 to 9.2. Fluorescence was measured on a 
SpectraMax miniMax300 imaging cytometer.  
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In vivo experiments 
All in vivo experiments were conducted under approval of the Université catholique de 
Louvain (UCL) authorities (Comité d’Ethique Facultaire pour l’Expérimentation Animale) 
according to national animal care regulations (authorization #2012/UCL/MD/005). 
 For spontaneous metastasis assays, 200,000 luciferase-expressing 4T1 were 
subcutaneously injected in the flank of 7 weeks-old syngeneic BALB/cJRj female mice 
(Janvier). Primary tumor growth was regularly measured over time with a caliper, and 
tumor volume was calculated as previously described (33). Primary tumors were 
surgically resected between day 24 and 31, i.e., when their average diameter reached 
10 mm. They were embedded in paraffin, and two 5 µm-thick central sections for each 
tumor were stained with hematoxylin and eosin (H&E) and immunostained for cleaved 
caspase 3 (Cell signaling #9661) or Ki-67 (Cell signaling #12202). All mice were 
sacrificed at day 38 by cervical dislocation. Ten minutes before sacrifice, mice were i.p. 
injected with 0.15 mg/g bodyweight of luciferin (PerkinElmer). Five minutes after 
sacrifice, lungs were inflated with a 15 mg/mL luciferin solution and bathed in the same 
solution for 5 min. Chemiluminescence was acquired on harvested lungs during 4 min 
with a Xenogen IVIS 50 bioluminescence imaging system (PerkinElmer), and quantified 
with the Living Image software (PerkinElmer). Lungs were further examined under a 
Stemi 2000-C dissection microscope to count surface metastases. They were then 
embedded in paraffin, and 5 µm-thick lung sections (2 different plans for each lobe of 
each animal) were stained with H&E. All slices were scanned with a SCN400 bright field 
slide scanner (Leica) at 20x magnification. Quantitative data were obtained with the 
Tissue IA software (Leica). 
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Statistics 
Except in dot plots that show individual values and group averages, all data show means 
± SEM (error bars are sometimes smaller than symbols). n indicates the total number of 
replicates. Student's t test, one-way ANOVA with Dunnett's or Bonferroni's post-hoc 
tests, and two-way ANOVA on matched values with Bonferroni's post-hoc test were 
applied where indicated. P < 0.05 was considered to be statistically significant.  
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Results 
MCT1 promotes cancer cell migration and invasion 
To address the contribution of MCT1 to cancer metastasis, we used human SiHa cervix 
squamous carcinoma cells and 4T1 mouse mammary carcinoma cells. Both cell lines 
express MCT1 (Fig. S1A). 
In the absence of exogenous lactate except from serum, MCT1 silencing using 
siMCT1 or shMCT1 and MCT1 deletion using a CRISPR-Cas9 strategy (Fig. S1A) did 
not affect SiHa cell count (Fig. S1B) but reduced SiHa cell migration (Fig. 1A) and 
invasion (Fig. 1B) towards serum by about 50 to 80%. A scratch test further revealed 
that SiHa cell migration was sustainably inhibited by shMCT1 over 48 h (Fig. S1C). 
Thus, SiHa cell migration and invasion were inhibited upon MCT1 silencing or deletion. 
Of note, shMCT1, but not CRISPR-MCT1, was associated with an increase in MCT4 
expression (Fig. S1A). Expression of CD147/basigin was unchanged. Of further note, 
providing lactate to SiHa cells barely affected their migratory activity. In transwells, 20 
mM of lactate (34) delivered in the upper compartment significantly reduced SiHa 
migration by about 10%, and lactate did not act as a chemoattractant (Fig. S1D). 
 That MCT1 promotes cancer cell migration was verified using 4T1 mouse 
mammary carcinoma cells (see metabolic characterization below). MCT1 silencing with 
shMCT1a or shMCT1b (Fig. S1A) did not affect clonogenicity (Fig. S1E) but reduced 
4T1 cell migration by about 65% (Fig. 1C) and invasion by about 40% (Fig. 1D). There 
was no increase in MCT4 expression upon MCT1 silencing (Fig. S1A). 
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Suppressing MCT1 expression decreases lactic acid efflux from cancer cells 
Because cancer cell metabolism can impact migration, invasion and metastasis (35), we 
characterized the metabolic consequences of MCT1 silencing/deletion in SiHa and 4T1 
cells in the same conditions as in migration and invasion assays.  
In SiHa cells, shMCT1 did not modify glucose consumption (Fig. 2A) but reduced 
lactate release (Fig. 2B), and lactate accumulated intracellularly (Fig. S2A). shMCT1 
further decreased the extracellular acidification rate (ECAR) directly attributable to 
glycolysis (Fig. 2C), whereas intracellular pH slightly decreased (Fig. S2B). pH at the 
outer side of the cell membrane was less acidic (Fig. S2C). Similarly, deleting MCT1 
using CRISPR-Cas9 resulted in decreased lactate release (Fig. 2B) and decreased 
glycolytic ECAR (Fig. 2C) with unchanged glucose consumption (Fig. 2A). Lactate 
accumulated intracellularly (Fig. S2A). Thus, inhibiting MCT1 expression decreased the 
glycolytic efficiency of SiHa cells. Oxidative activity was measured on a Seahorse XF96 
oximeter. Compared to shCTR, shMCT1 did not modify the basal OCR of SiHa cells or 
their maximal respiratory capacity (Fig. 2D-F). In contrast, both parameters increased in 
SiHa-CRISPR-MCT1 compared to wild-type SiHa cells (Fig. 2D-F). 
 Metabolic characterization was also performed for 4T1 cells. Compared to 
shCTR, shMCT1a and shMCT1b decreased 4T1 glucose consumption (Fig. 2G) and 
lactate release (Fig. 2H), which was associated to a decreased glycolytic ECAR (Fig. 
2I). Basal and maximal OCR increased (Fig. 2J), especially with shMCT1b that was 
more efficient than shMCT1a to repress MCT1 protein expression in these cells (Fig. 
S1A). 
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The transporter activity of MCT1 does not participate in MCT1-dependent cancer 
cell migration and invasion 
An acidic environment promotes cancer cell migration, invasion and metastasis (35). 
Because as a passive transporter MCT1 can transport lactic acid bidirectionally, we 
investigated whether MCT1 activity is involved in the prometastatic phenotype. Inhibition 
of MCT1 with increasing doses of AR-C155858 (27) or 10 µM of AZD3965 (24) did not 
significantly modify glucose consumption (Fig. 3A) but reduced lactate release (Fig. 3B) 
by SiHa cells, and lactate accumulated intracellularly (Fig. S3A). AR-C155858 also 
reduced proton export by the cells (Fig. 3C) and promoted intracellular acidification (Fig. 
S3B). At 10 µM, it did not affect the OCR of the cells (Fig. S3C) or their number (Fig. 
S3D). However, despite the striking similarity of the metabolic effects seen with MCT1 
suppression and its inhibition, AR-C155858 did not inhibit SiHa cell migration (Fig. 3D) 
or invasion (Fig. 3E). AZD3965 (10 µM) did not impair SiHa cell migration (Fig. 3D). Of 
note, we verified that neither AR-C155858 nor AZD3965 altered MCT1, MCT4 and 
CD147 expression in the cells (Fig. S3E).  
 In 4T1 cells, AR-C155858 was used at a 10 nM concentration that did not affect 
cell number (Fig. S3F) but efficiently decreased glucose consumption (Fig. 3F) and 
lactic acid release (Fig. 3G and Fig. S3G). AR-C155858 did not affect 4T1 cell migration 
(Fig. 3H) or invasion (Fig. 3I). MCT1 was also re-expressed in 4T1-shMCT1a cells, and 
we opted for a human sequence resistant to the anti-mouse shRNA (hMCT1+), which 
restored 4T1 cell migration (Fig. 3J).  
To demonstrate that MCT1 promotes cancer cell migration independently of its 
transporter activity, we generated a Cas9-resistant and transport-inactive (38K>R, 
302D>R, 306R>D) (29) version of the transporter (hMCT1-). Expression of hMCT1- in 
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SiHa-CRISPR-MCT1 cells restored migration (Fig. 3K). EGFP was used in control 
experiments, evidencing that about 50% of the cells were efficiently transfected (Fig. 
S3H). 
 
Highly invasive cancer cells have a high MCT1 expression that promotes their 
migration and invasion 
To further analyze the relationship between MCT1 expression and the prometastatic 
phenotype, we used SiHa-F3 and SiHa-ρ0 cells, which have been reported to be more 
migratory and invasive than SiHa-WT (25).  
SiHa-F3 had increased MCT1 expression compared to SiHa-WT, whereas MCT4 
expression was decreased and CD147 expression was unmodified (Fig. 4A). Compared 
to SiHa-WT, SiHa-F3 cells had increased glucose consumption (Fig. S4A) and lactate 
release (Fig. S4B), increased glycolytic ECAR (Fig. S4C) and increased basal OCR 
(Fig. S4D). They were more migratory than SiHa-WT cells (Fig. 4B and Fig. S4E). 
Conversely, silencing MCT1 with shMCT1 in SiHa-F3 cells (Fig. 4A) decreased lactate 
release (Fig. S4B) and increased cell respiration (Fig. S4D). shMCT1, but not AR-
C155858, significantly decreased SiHa-F3 cell migration and invasion (Fig. 4B-C and 
Fig. S4E). 
 Similarly, SiHa-ρ0 cells expressed more MCT1 compared to parental cells (Fig. 
4D). Their in vitro migration and invasion was almost fully inhibited upon MCT1 silencing 
(Fig. 4E). 
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MCT1 expression, but not its transport activity, triggers NF-κB in cancer cells  
We next sought to identify a mechanism through which MCT1 expression could control 
cancer cell migration independently of its activity as a transporter. Based on a previous 
report by Zhao et al. (36), we focused on transcription factor NF-κB. Compared to SiHa-
WT, SiHa-F3 and SiHa-ρ0 cells had a higher phospho-Ser536-p65/total p65 ratio (Fig. 
S5A). Conversely, both SiHa-shMCT1 and SiHa-CRISPR-MCT1 had a decreased 
phospho-Ser536-p65 (human sequence)/total p65 ratio than control cells (Fig. 5A). 
Upstream of NF-κB pathway, MCT1 deletion decreased IκKα but not IκKβ expression 
(Fig. 5B). Similarly, the phospho-Ser536-p65/total p65 ratio was decreased in 4T1 cells 
expressing shMCT1a or shMCT1b (Fig. 5C) and restored when 4T1-shMCT1 cells 
expressed hMCT1+ (Fig. S5B). Of note, expression of mutated/inactivated hMCT1- in 
SiHa-CRISPR-MCT1 cells also increased p65 Ser536-phosphorylation (Fig. S5C), but 
cellular stress induced by the transfection procedure had a confounding effect. 
Because changes in MCT1 expression but not its pharmacological inhibition by 
AR-C155858 or AZD3965 (Fig. S5D) influenced p65 phosphorylation, we tested whether 
NF-κB activation was sufficient to resume MCT1-deficent cell migration. NF-κB 
activation by TNFα or TPA (Fig. S5E) restored SiHa-CRISPR-MCT1 cell migration (Fig. 
5D), and this effect was fully blocked by BMS-345541, a highly specific NF-κB inhibitor 
(37) (Fig. S5E). NF-κB inhibition and MCT1 deletion had no additive antimigratory 
effects (Fig. 5E), which, together with the above data, indicated that NF-κB acts 
downstream of MCT1 to control cancer cell migration. 
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MCT1 silencing inhibits spontaneous 4T1 breast cancer metastasis to the lungs 
SiHa cells are only weakly metastatic in SCID mice (38). To evaluate the contribution of 
MCT1 expression to metastasis, we therefore used the 4T1 model where primary tumors 
spontaneously metastasize to the lungs of immunocompetent syngeneic mice (39). 
Luciferase-expressing 4T1-shCTR, 4T1-shMCT1a and 4T1-shMCT1b cells generated 
subcutaneous primary tumors with similar growth rates (Fig. S6A), necrotic cores, and 
apoptotic and proliferative fractions (Fig. S6B). However, MCT1 silencing strongly 
decreased lung metastasis detected by ex vivo bioluminescence (Fig. 6A) and direct 
counts (Fig. 6B). These data were confirmed by histological analysis showing fewer 
(Fig. 6C left) and smaller (Fig. 6C right) metastases per total lung area in 4T1-shMCT1a 
and 4T1-MCT1b compared to 4T1-shCTR tumor-bearing mice.  
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Discussion 
This study aimed to clarify the contribution of MCT1 to cancer metastasis. We report that 
MCT1 promotes cancer cell migration and invasion independently of its activity as a 
transporter. Consequently, MCT1 silencing or deletion, but not its pharmacological 
inhibition, repressed these phenotypes. Silencing MCT1 further inhibited spontaneous 
metastatic dissemination in mice. 
 Since its identification as a transporter of lactic acid in cancer cells in 1994 (40) 
and in tumors in 2001 (41), MCT1 expression has been reported in a wide variety of 
human cancers, including head and neck, breast, lung, stomach, colon, bladder, 
prostate and cervix cancers, as well as gliomas (see references in (5)). Its transporter 
activity has been positively linked to the metabolic capability of cancer cells to switch 
substrates depending on their local bioavailability (5) and to tumor angiogenesis (13). 
However, to our knowledge and despite converging clues (12, 21-24, 36), there was no 
experimental demonstration that MCT1 contributes to tumor metastasis in vivo. The 
closest related study is probably that of Zhao et al. (36) who claimed that downregulation 
of MCT1 expression inhibits tumor metastasis, but these authors did not perform any in 
vivo experiments. Our demonstration that MCT1 promotes spontaneous tumor 
metastasis in immunocompetent mice thus confirms these previous hypothetical clues. 
Together with our precedent observations, it reveals that MCT1 facilitates three main 
strategies displayed by cancer cells in harsh microenvironmental conditions: to adapt to 
the environment (metabolic plasticity), to modify the environment (angiogenesis) and to 
leave the environment (migration, invasion and metastasis). Thus, high MCT1 
expression facilitates cancer cell migration, invasion and metastasis. This characteristic 
Research. 
on September 20, 2017. © 2017 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 21, 2017; DOI: 10.1158/0008-5472.CAN-17-0764 
20 
 
is shared by different cancer cell types, including superinvasive SiHa-F3 and SiHa-ρ0 
cervix adenocarcinoma cells that depend on high MCT1 expression for migration and 
invasion (this study) and clinical non‑small cell lung carcinomas (42) where metastatic 
lesions express higher levels of MCT1 than primary tumors. The latter observation 
further indicates that MCT1 could contribute to the growth of established metastases. 
 As a passive transporter, MCT1 can operate bidirectionally, which explains why it 
facilitated lactic acid export from SiHa and 4T1 cells in our experimental conditions. 
Accordingly, MCT1-deficient cells had a reduced capacity to acidify culture medium in 
general and the outer side of the cell membrane in particular. Generally, extracellular 
acidification triggers cell invasion by promoting protease activity and altering cellular 
adhesion (35, 43), but MCT1 turned out not to be an essential contributor to pH-
dependent invasion. Indeed, while MCT1 inhibitors AR-C155858 and AZD3965 
effectively reduced lactic acid release by the cells, they did not inhibit migration and 
invasion even when used at doses higher than what can be safely achieved in vivo. This 
observation can be related to the presence of several other sources of acidity, including 
CO2, as notably evidenced by experiments that showed that glycolysis-deficient cancer 
cells that produce negligible amounts of lactic acid are as effective as glycolysis-
competent cells to lower extracellular pH down to 6.7 (44). Thus, in agreement with Gray 
et al. (24) but not with Izumi et al. (22) who used nonselective MCT inhibitors, we report 
that MCT1 promotes cancer cell migration and invasion independently of its transporter 
activity. In support of this conclusion, expression of a transport-inactivated version of 
MCT1 lacking proton- and lactate-binding sites in MCT1-deleted cancer cells rescued 
migration.  
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 Mechanistically, based on previous observations (36), we confirmed that NF-κB is 
a downstream effector of MCT1 for cancer cell migration. Indeed, MCT1 deletion 
reduced the expression of IκKα (a catalytically active constituent of the IκB kinase 
complex that normally triggers NF-κB activation) and reduced NF-κB activity and cell 
migration, and MCT1 deletion and NF-κB inhibition had no additive effects on inhibition 
of cancer cell migration. Conversely, NF-κB activation restored the migration of MCT1-
deficient cells, which was achieved either with pharmacological NF-κB activators or 
through MCT1 re-expression in deficient cells. Beyond its role as a transporter, MCT1 
physically interacts with proteins, notably carbonic anhydrase II (CAII) (45), hyaluronan 
receptor CD44 (46) and CD147 (19). While cytosolic CAII regulates MCT1 transporter 
activity (47) and CD44 is a stem cell marker, transmembrane glycoprotein CD147, also 
known as extracellular matrix metalloproteinase inducer (EMMPRIN), is well-known to 
promote tumor metastasis (48). Interestingly, through a yet unknown mechanism, 
CD147 has been reported to activate NF-κB in cardiomyocytes (49) and in fibroblasts 
(50). Because interaction mutually stabilizes both proteins at the cell membrane, it would 
have been tempting to propose that MCT1-CD147 complexes could promote cancer cell 
migration and invasion through CD147-dependent NF-κB activation. However, CD147 
expression was not altered in our MCT1-defective cell models, most probably because 
CD147 interacts with other proteins at the cell membrane, notably MCT4 (19). Thus, 
how MCT1 expression represses IκKα expression and activates NF-κB in cancer cells 
independently of lactate fluxes remains an open question. Hypotheses that merit to be 
addressed relate to the turnover rate of CD147 in MCT1-deficient cells, as the 
extracellular domain of CD147 has been proposed to control IκB kinase expression (50) 
(of which IκKα is a constituent) and to the possibility that MCT1 itself would initiate 
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intracellular signaling through yet unknown protein-protein interaction(s). MCT1 could 
also further trigger NF-κB-independent pathways to promote cancer cell migration. 
 Conclusively, MCT1 activates NF-κB independently of its transporter activity, 
which promotes cancer cell migration, invasion and metastasis. We therefore believe 
that MCT1 inhibitors do not have the potential to achieve a clinical prevention of tumor 
metastasis, which of course does not impact their therapeutic interest as antimetabolic 
and anti-angiogenic drugs in established (primary and secondary) tumors.  
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Legends of the Figures 
Figure 1. MCT1 silencing or deletion decreases cancer cell migration and 
invasion. A-B, MCT1 was silenced in SiHa cancer cells using siRNA (SiHa-siMCT1), 
shRNA (SiHa-shMCT1) or deleted using a CRISPR-Cas9 strategy (SiHa-CRISPR-
MCT1). A, Comparative migration of SiHa-siCTR versus SiHa-siMCT1 (left, n = 8), 
SiHa-shCTR versus SiHa-shMCT1 (middle, n = 11-12) and in SiHa-WT versus SiHa-
CRISPR-MCT1 (right, n = 6) in a Boyden chamber with 0.15% FBS as chemoattractant. 
Upper panels show representative pictures (bars = 100 µm). B, Comparative invasion of 
SiHa-shCTR versus SiHa-shMCT1 (left, n = 6) and in SiHa WT versus SiHa-CRISPR-
MCT1 (right, n = 8) in a Boyden chamber with 5% FBS as chemoattractant. Upper 
panels show representative pictures (bars = 100 µm). C-D, MCT1 was silenced in 4T1 
mouse mammary carcinoma cells using 2 different shRNAs (4T1-shMCT1a and 4T1-
shMCT1b). C, Cell migration in a Boyden chamber (n = 16). Upper panels show 
representative pictures (bars = 100 µm). D, Cell invasion in a Boyden chamber (n = 25-
26). Upper panels show representative pictures (bars = 100 µm). ** P < 0.01, *** P < 
0.005; by Student’s t test (A, B) or by one-way ANOVA with Dunnett’s post-hoc test (C, 
D). 
 
Figure 2. MCT1 silencing or deletion decreases lactic acid efflux from SiHa and 
4T1 cells. A-F, MCT1 was silenced in SiHa cancer cells using shRNA (SiHa-shMCT1) 
or deleted using CRISPR-Cas9 (SiHa-CRISPR-MCT1). A, Glucose consumption by 
SiHa-shCTR versus SiHa-shMCT1 (left, n = 6) and in SiHa WT versus SiHa-CRISPR-
MCT1 (right, n = 5-6). B, Lactate release by SiHa-shCTR versus SiHa-shMCT1 (left, n = 
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6) and in SiHa WT versus SiHa-CRISPR-MCT1 (right, n = 5-6). C, Glycolytic 
extracellular acidification rate (ECAR) measured with a Seahorse analyzer in SiHa-
shCTR versus SiHa-shMCT1 (left, n = 15) and in SiHa WT versus SiHa-CRISPR-MCT1 
(right, n = 7-8). D, Oxygen consumption rate (OCR) measured with a Seahorse analyzer 
in SiHa-shCTR versus SiHa-shMCT1 (left, n = 13-15) and in SiHa WT versus SiHa-
CRISPR-MCT1 (right, n = 7-8). E, Basal mitochondrial OCR calculated from D. F, 
Maximal mitochondrial OCR calculated from D. G-J, MCT1 was silenced using 2 
different shRNAs in 4T1-shMCT1a and 4T1-shMCT1b cells. G, Glucose consumption (n 
= 3). H, Lactate release (n = 3). I, Glycolytic ECAR (n = 7). J, OCR, basal mitochondrial 
OCR and maximal mitochondrial OCR (n = 7). ns P > 0.05, * P < 0.05, *** P < 0.005; by 
Student’s t test (A-F) or one-way ANOVA with Dunnett’s post-hoc test (G-J).  
 
Figure 3. Pharmacological MCT1 inhibition decreases lactic acid efflux but does 
affect cancer cell migration and invasion. A-I, MCT1 activity was inhibited in cancer 
cells by AR-C155858 or AZD3965. Vehicle was 0.1% DMSO. A, Glucose consumption 
by SiHa-WT cells treated with AR-C155858 (left, n = 8-9) or AZD3965 (right, n = 5-6) 
versus vehicle. B, Lactate release by SiHa-WT cells treated with AR-C155858 (left, n = 
8-9) or AZD3965 (right, n = 5-6) versus vehicle. C, Glycolytic extracellular acidification 
rate (ECAR) of SiHa-WT cells (n = 6). D, SiHa-WT cell migration when treated with AR-
C155858 (left, n = 15) or AZD3965 (right, n = 12) versus vehicle in a Boyden Chamber. 
Upper panels show representative pictures (bars = 100 µm). E, SiHa WT cell invasion in 
a Boyden Chamber (n = 10). Upper panels show representative pictures (bars = 100 
µm). F, Glucose consumption of 4T1 cells (n = 6). G, Lactate release by 4T1 cells (n = 
6). H, 4T1 cell migration (n = 12). Upper panels show representative pictures (bars = 
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100 µm). I, 4T1 cell invasion (n = 12). Upper panels show representative pictures (bars 
= 100 µm). J, Migration of 4T1 cells silenced for MCT1 (shMCT1a) and expressing or 
not wild-type human MCT1 (hMCT1+) (n = 8). Western blots show MCT1 and β-actin 
expression (n = 3). Upper panels show representative pictures (bars = 100 µm). K, 
Migration of SiHa cells deleted for MCT1 using CRISPR-Cas9 (SiHa-CRISPR-MCT1) 
and expressing or not mutated/inactive human MCT1 (hMCT1-) (n = 12). Western blots 
show MCT1 and HSP-90 expression (n = 2). Upper panels show representative pictures 
(bars = 100 µm). ns P > 0.05, * P < 0.05, ** P < 0.01, *** P < 0.005; by one-way ANOVA 
with Dunnett’s post-hoc test (A-B left) or by Student’s t test (A-B right, C-K). 
 
Figure 4. Superinvasive SiHa-F3 and SiHa-ρ0 cells have high MCT1 expression 
that promotes migration and invasion. A-F, Where indicated, MCT1 was silenced 
using siMCT1 or shMCT1. A, Representative western blots of MCT1, MCT4, CD147 and 
HSP-90 expression. B, SiHa-F3 migration (left, n = 4) and invasion (right, n = 17-18) in 
Boyden chambers. Upper panels show representative pictures (bars = 100 µm). C, 
SiHa-F3 migration (left, n = 10) and invasion (right, n = 12) upon treatment with 10 µM of 
AR-C155858 or vehicle. Upper panels show representative pictures (bars = 100 µm). D, 
Representative western blots of MCT1, MCT4, CD147 and β-actin expression. E, SiHa-
ρ0 migration (left, n = 4) and invasion (right, n = 8). Upper panels show representative 
pictures (bars = 100 µm). ns P > 0.05, * P < 0.05, *** P < 0.005 versus control; ### P < 
0.005 versus SiHa-F3-shCTR; $$$ P < 0.005 versus SiHa-ρ0-siCTR; by one-way ANOVA 
with Dunnett’s post-hoc test (B left, E left) or Student’s t test (B right, C, E right). 
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Figure 5. NF-κB controls MCT1-dependent cancer cell migration. A, Comparison of 
phospho-Ser536-p65, total p65 and HSP-90 protein expression in SiHa-shCTR versus 
SiHa-shMCT1 (n = 6) and SiHa-WT versus SiHa-CRISPR-MCT1 (n = 9). B, 
Representative blots of IκKα, IκKβ and HSP-90 in SiHa-WT and SiHa-CRISPR-MCT1 
cells (n = 6-12). C, Comparison of phospho-Ser536-p65, total p65 and β-actin protein 
expression in 4T1-shCTR versus 4T1-shMCT1a and 4T1-shMCT1b cells (n = 9). D, 
Migration in a Boyden chamber of SiHa-CRISPR-MCT1 cells pretreated for 2 h ± TNFα 
(left, n = 12) or TPA (right, n = 15) with or without NF-κB inhibitor BMS-345541. Upper 
panels show representative pictures (bars = 100 µm). E, Migration in a Boyden chamber 
of SiHa-WT and SiHa-CRISPR-MCT1 cells pretreated for 24 h and treated during the 
assay ± BMS-345541 (n = 8). Upper panels show representative pictures (bars = 100 
µm). ns P > 0.05, * P < 0.05, ** P < 0.01, *** P < 0.005 versus first column or as 
indicated; # P < 0.05, ## P < 0.01 versus second column; by Student's t test (A) or one-
way ANOVA with Dunnett’s (C-D) or Bonferroni’s (E) post-hoc test. 
 
Figure 6. MCT1 silencing decreases spontaneous 4T1 metastasis. Spontaneous 
lung metastasis assay using luciferase-expressing 4T1-shCTR, 4T1-shMCT1a and 4T1-
shMCT1b cancer cells that were implanted subcutaneously to form primary tumors in 
immunocompetent syngeneic mice. Lungs were analyzed 38 days after primary tumor 
implantation. A, Representative pictures and quantification of the luciferase signal in 
mouse lungs (n = 8-9). B, Quantification of the number of surface metastases in mouse 
lungs (n = 8-9). C, Representative micrographs of H&E-stained lung sections where 
metastasis are indicated with an asterisk and quantification of the number of metastases 
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(left) and metastatic area (right) normalized to lung area (n = 8-9). * P < 0.05, ** P < 
0.01, *** P < 0.005; by one-way ANOVA with Dunnett’s post-hoc test (A-C). 
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